Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Genetic testing of early breast tumours could allow patients to go without chemo

2018 ASCO Annual Meeting

Published: 3 Jun 2018

Views: 1570

Rating:

Save

Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA

Dr Sparano presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the TAILORx trial.

The results show that 70% of women with early HR / HER2- breast cancer could be spared chemotherapy, based on the results from a 21gene assay.

For more on these results, watch his interview with ecancer and read our news coverage here.

Slides from this presentation are available here.

Related Videos

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall...

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )

The Southeast Asian Breast Cancer Symposium; background, aims and successes

Carolyn Taylor - Executive Director, Global Focus on Cancer

The Southeast Asian Breast Cancer Symposium; background, aims and successes ( Carolyn Taylor - Executive Director, Global Focus on Cancer )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for August 11th - 17th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 11th - 17th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Choosing Wisely in implementing prevention, screening and early detection...

Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda

Choosing Wisely in implementing prevention, screening and early detection programs in Africa ( Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda )

More from ecancer